Xenoport, Inc. (delisted) (NASDAQ:XNPT)
Historical Stock Chart
5 Years : From Oct 2011 to Oct 2016
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its
first quarter financial results on May 2, 2012 at approximately 4:30
p.m. Eastern Time. The company will host a conference call at 5:00 p.m.
Eastern Time that same day. A replay of the call will be available for
one week following the event.
To access the conference call via the Internet, go to www.XenoPort.com.
Please join the call at least 15 minutes prior to the start to ensure
time for any software downloads that may be required.
To access the live conference call via phone, dial 1-888-275-3514.
International callers may access the live call by dialing 706-679-1417.
The reference number to enter the call is 73444304.
The replay of the conference call may be accessed that same day after
8:00 p.m. Eastern Time, via the Internet, at www.XenoPort.com,
or via phone at 1-800-642-1687 for domestic callers, or 706-645-9291 for
international callers. The reference number to enter the replay of the
call is 73444304.
XenoPort is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. Horizant®
(gabapentin enacarbil) Extended-Release Tablets is XenoPort’s first
FDA-approved product. GlaxoSmithKline holds commercialization rights and
certain development rights for Horizant in the United States.
Regnite® (gabapentin enacarbil) Extended-Release Tablets is
approved for the treatment of moderate-to-severe primary restless legs
syndrome in Japan. Astellas Pharma Inc. holds all development and
commercialization rights for Regnite in Japan and five Asian
countries. XenoPort holds all other world-wide rights and has
co-promotion and certain development rights to gabapentin enacarbil in
the United States. XenoPort’s pipeline of product candidates includes
potential treatments for patients with postherpetic neuralgia,
spasticity and Parkinson’s disease.
To learn more about XenoPort, please visit the company Website at www.XenoPort.com.
XENOPORT is a registered trademark of XenoPort, Inc.
Horizant is a registered trademark of GlaxoSmithKline.
Regnite is a registered trademark of Astellas Pharma Inc.